In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 35914259.
- Also identified by DOI 10.7326/J22-0056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Levin MJ, Ustianowski A, De Wit S, et al. <b>Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.</b> N Engl J Med. 2022;386:2188-200. 35443106.
Medical subject headings
- COVID-19